Research progress of indoleamine 2,3-dioxygenase inhibitors - Wikidata - awgldk - TriplyDB

Research progress of indoleamine 2,3-dioxygenase inhibitors

Research progress of indoleamine 2,3-dioxygenase inhibitors

http://www.wikidata.org/entity/Q28257093

about

Clinical significance of T cell metabolic reprogramming in cancer Immune Mechanisms in Myelodysplastic Syndrome Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors Development of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis.A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy Carbon Disulfide (CS2) Interference in Glucose Metabolism from Unconventional Oil and Gas Extraction and Processing Emissions Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses.Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study.The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.The role of metabolic reprogramming in T cell fate and function.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.Evaluation of radiofluorinated carboximidamides as potential IDO-targeted PET tracers for cancer imaging.Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.Discovery of IDO1 and DNA dual targeting antitumor agents.An Expanded Neuroimmunomodulation Axis: sCD83-Indoleamine 2,3-Dioxygenase—Kynurenine Pathway and Updates of Kynurenine Pathway in Neurologic Diseases.1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma.

P2860

Q26741974-E4BB9AE8-7153-45B2-AD32-E38B8D23AEAF Q26744500-1498D5BF-D8E2-49EE-B27D-38F262AFD1CD Q26769884-5D4B5EEA-D083-464C-84AB-5F70B021C6D7 Q28818166-A55326CE-4FE8-43B2-87DA-7864DA3F31A9 Q36033944-88A33D98-EF88-4769-BC4D-CCC9DC2CFC1E Q36635458-71F674C4-B069-4E74-BA1B-E37A1F126B03 Q36738206-F4E98A4A-7C4E-45FF-803D-6E7C1FE9EFD8 Q36810606-1EA2EC75-156C-45A4-93BF-C30A0E54FBF9 Q38647699-92CF27B1-B287-41C7-A188-617AAD7C97E6 Q38675915-EF4EFB45-1872-4390-86B9-14216FACE9D6 Q38719858-9772138E-DF24-4F9E-9FE0-A693E037AA6E Q39207529-48B16D6E-88B6-406D-8FAA-F286ECC6AE49 Q39262474-DC3771A8-BBDD-46A5-9197-0471633A1633 Q40816321-1EB50D7F-42E6-4B50-8F43-CD3691BA8933 Q41470807-323EE66E-3FAA-4B4F-B963-266A5E28A5F5 Q48177244-03F15FFD-87E6-4A9D-B832-321DBBDBB128 Q48589619-ADB9C472-3060-45DE-90F9-23A50CFFA9EA Q55381445-CECE2A29-19D9-4D07-9C7F-F4C6760A6375 Q55516059-30B0E6CB-972E-418A-B413-F3A5EBD7C587

P2860

Research progress of indoleamine 2,3-dioxygenase inhibitors

http://www.wikidata.org/entity/Q28257093

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Research progress of indoleamine 2,3-dioxygenase inhibitors

@ast

Research progress of indoleamine 2,3-dioxygenase inhibitors

@en

Research progress of indoleamine 2,3-dioxygenase inhibitors

@nl

type

label

Research progress of indoleamine 2,3-dioxygenase inhibitors

@ast

Research progress of indoleamine 2,3-dioxygenase inhibitors

@en

Research progress of indoleamine 2,3-dioxygenase inhibitors

@nl

prefLabel

Research progress of indoleamine 2,3-dioxygenase inhibitors

@ast

Research progress of indoleamine 2,3-dioxygenase inhibitors

@en

Research progress of indoleamine 2,3-dioxygenase inhibitors

@nl

P1433

Q28257093-F890957F-6C03-41A6-B9E3-862E28C022CB

P1476

Q28257093-5CC297BC-94E9-464A-91A8-BF0BAF2F016E

P2093

Q28257093-1C65780C-165D-4D6B-A365-BE177619B701

Q28257093-1E5EFF3C-5899-40F6-B776-77FAE1E6239E

Q28257093-1E99B3EE-26C1-41E2-9B68-66447D1A73BD

Q28257093-C0957EE8-83E9-47CD-A18F-A88FC753D5A7

Q28257093-DE33AF9E-415D-4BA8-BBE9-2865C32834B0

Q28257093-EC47D946-743C-4B9D-833F-089BA0131FFB

P2860

Q28257093-07835728-5288-4EED-8557-B9AA588BCA14

Q28257093-0793AAA1-DD9E-4322-866B-0B6CE6BE35B5

Q28257093-0EF90E75-70FE-4A3F-BF90-64204CA3B5DE

Q28257093-155F5A2A-ABE6-4207-94EB-D97D1BC7F7CE

Q28257093-15CD73A1-95B1-40DD-BE5E-FBF7BD009338

Q28257093-2432FE3F-2799-4DFF-A031-E6F4FE87F95E

Q28257093-25FF8989-0D84-4007-8016-A737887F75CD

Q28257093-284FE9E0-579E-4902-8840-F18F0BDE4447

Q28257093-2C3FA87C-2DBD-454E-BA21-CBDFD516A8B2

Q28257093-3855EE78-9D08-48C7-BC0E-CD9E32610805

P304

Q28257093-D9F434B7-DCEC-455F-8623-804A2A574ED7

P31

Q28257093-AFB6132A-9976-4E59-AAD2-43106CFAA38D

P3181

Q28257093-F3FCF24C-0F7A-40B4-BFAF-3B82DB339099

P356

Q28257093-7034F1C9-8DD7-4B1C-8DEA-8B747A6FCBC4

P407

Q28257093-65323BDA-58AD-4694-9ED7-132BD51DD7C7

P433

Q28257093-5B3FED72-52E6-4DA3-8454-436AB7956FC3

P478

Q28257093-EA67BFDD-19EF-43B8-A70B-38555BA9AAE4

P577

Q28257093-B1661C4E-60DC-4273-B8E6-2A5B89E8C226

P5875

Q28257093-2CC1F878-CE28-49CE-B863-272444D836BA

P698

Q28257093-D3AEDF4A-83F6-4D24-B854-2FB898A55C01

P3181

P356

P1433

Future Medicinal Chemistry

P1476

Research progress of indoleamine 2,3-dioxygenase inhibitors

@en

P2093

Liping Sun

http://www.w3.org/2001/XMLSchema#string

Sen Feng

http://www.w3.org/2001/XMLSchema#string

Tianze Jiang

http://www.w3.org/2001/XMLSchema#string

Yingying Sun

http://www.w3.org/2001/XMLSchema#string

Zhichao Yin

http://www.w3.org/2001/XMLSchema#string

Zhiyu Li

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

Prevention of allogeneic fetal rejection by tryptophan catabolism

Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase

Virtual screening of chemical libraries.

Rational design of indoleamine 2,3-dioxygenase inhibitors.

Heme-Containing Oxygenases.

P304

185-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

764043

http://www.w3.org/2001/XMLSchema#string

P356

10.4155/FMC.14.151

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272421930

http://www.w3.org/2001/XMLSchema#string

P698

25686005

http://www.w3.org/2001/XMLSchema#string